Liquidia Technologies Inc (LQDA) - Total Liabilities
Based on the latest financial reports, Liquidia Technologies Inc (LQDA) has total liabilities worth $253.93 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Liquidia Technologies Inc cash conversion from operations to assess how effectively this company generates cash.
Liquidia Technologies Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Liquidia Technologies Inc's total liabilities have evolved over time, based on quarterly financial data. Check LQDA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Liquidia Technologies Inc Competitors by Total Liabilities
The table below lists competitors of Liquidia Technologies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Petroleum Engineering Corp
SHG:600339
|
China | CN¥97.35 Billion |
|
Autel Intelligent Technology Corp Ltd
SHG:688208
|
China | CN¥3.65 Billion |
|
Amedisys Inc
NASDAQ:AMED
|
USA | $940.48 Million |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥719.98 Million |
|
Trigano S.A.
PA:TRI
|
France | €1.19 Billion |
|
CI Financial Corp
TO:CIX
|
Canada | CA$10.53 Billion |
|
WesBanco Inc
NASDAQ:WSBC
|
USA | $23.66 Billion |
|
Zhejiang Yongtai Technology Co Ltd
SHE:002326
|
China | CN¥8.21 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Liquidia Technologies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Liquidia Technologies Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 11.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.92 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Liquidia Technologies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Liquidia Technologies Inc (2016–2024)
The table below shows the annual total liabilities of Liquidia Technologies Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $153.04 Million | +115.43% |
| 2023-12-31 | $71.04 Million | +83.20% |
| 2022-12-31 | $38.78 Million | +36.23% |
| 2021-12-31 | $28.46 Million | +0.06% |
| 2020-12-31 | $28.45 Million | -16.08% |
| 2019-12-31 | $33.89 Million | +10.30% |
| 2018-12-31 | $30.73 Million | -36.68% |
| 2017-12-31 | $48.54 Million | +81.57% |
| 2016-12-31 | $26.73 Million | -- |
About Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The comp… Read more